Idorsia Establishes US Commercial Operations, Leadership Team

Idorsia announced its expansion in the United States by establishing commercial operations. Located in Radnor, PA, the company has been established to further develop and embed Idorsia’s budding global commercial organization. Idorsia US will be led by Patricia “Patty” Torr, President and General Manager, who joined Idorsia in March 2020.

“Idorsia is a start-up like no other! Established just three years ago, a founding team of 650 employees started out with a rich experience of working together and a pipeline of early-stage assets. Today, the company employs over 800 professionals and the pipeline has made incredible progress. Most recently we have released outstanding results of two pivotal studies of an investigational therapy for insomnia, and we expect a steady flow of results from other late-stage assets over the next few years. We are therefore ramping up our activities in the US and creating our commercial operations to prepare for the launch of our first product,” Simon Jose, Chief Commercial Officer, said.

“I’m incredibly excited and honored to build the commercial footprint that will bring Idorsia’s robust pipeline of products from its world-class R&D engine to the United States market – changing the lives of many patients in need. The US healthcare system is complex and constantly evolving. The need to bring innovative medicines to fill unmet needs for patients is as important as ever. Idorsia is committed to building our US operations to bring creative solutions to the market based on our science and data. We have formed a talented and diverse leadership team to commercialize and realize the potential of our deep and broad pipeline. Each of the team members have exceptional experience of the pharma world, in their respective functional areas, as well as a strong entrepreneurial mindset. This combination will be critical to our success as we move a step closer to commercializing our first product in the US,” Patricia Torr, President and General Manager of Idorsia US, said.

“This is a very exciting time for Idorsia. Just three years after creation we are entering a new phase, as we move closer to our ambition of developing into a fully-fledged biopharmaceutical company, bringing our products from the bench to the bedside. For our new US team, they are starting-up with all the excitement that goes with creating something from scratch, but with the security of excellent data with our lead compound and a broad pipeline of compounds that each have the potential to significantly change the treatment options in their target disease. I am very proud that such experienced and talented people have decided to join Idorsia,” Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia, said.

Torr brings over 20 years of broad leadership experience and industry-leading results in pharmaceutical and biotech marketing and sales to Idorsia. She served as CSL Behring’s Vice President, Global Commercial Strategy for Thrombosis and Hemostasis; Shire Pharmaceuticals’ Executive Vice President Head of US Hematology; Johnson and Johnson’s Vice President US Sales and Marketing of the Cardiovascular and Institutional Business and other senior roles at GlaxoSmithKline and AstraZeneca. Working across all stages of the product lifecycle from preclinical to launch to patent expiration and across therapeutic categories, she has forged a reputation for bringing successful products to market: while leading sales and marketing efforts for first-in-class Xa inhibitor Xarelto at J&J, Torr launched six indications in 18 months and achieved over $2 billion in sales. Torr earned a B.S. in Public Health Education from East Carolina University and an MBA in Marketing from St. Joseph’s University.